Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?

Group 1 - iTeos Therapeutics, Inc. (ITOS) shares have increased by 31.6% over the past four weeks, closing at $7.50, with a mean price target of $23.33 indicating a potential upside of 211.1% [1] - The average price targets from analysts range from a low of $15 to a high of $47, with a standard deviation of $12.21, suggesting a high degree of variability in estimates [2] - Analysts show strong agreement on ITOS's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - Recent revisions in earnings estimates for ITOS have shown two estimates moving higher and one lower, resulting in a 9.4% increase in the Zacks Consensus Estimate [12] - ITOS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [13]